Soft Interaction in Liposome Nanocarriers for Therapeutic Drug Delivery

Overview

Journal Nanomaterials (Basel)

Date 2017 Mar 25

PMID 28335253

Citations 39

Authors

Domenico Lombardo

Pietro Calandra

Davide Barreca

Salvatore Magazu

Mikhail A Kiselev

Affiliations

Soon will be listed here.

Abstract

The development of smart nanocarriers for the delivery of therapeutic drugs has experienced considerable expansion in recent decades, with the development of new medicines devoted to cancer treatment. In this respect a wide range of strategies can be developed by employing liposome nanocarriers with desired physico-chemical properties that, by exploiting a combination of a number of suitable soft interactions, can facilitate the transit through the biological barriers from the point of administration up to the site of drug action. As a result, the materials engineer has generated through the bottom up approach a variety of supramolecular nanocarriers for the encapsulation and controlled delivery of therapeutics which have revealed beneficial developments for stabilizing drug compounds, overcoming impediments to cellular and tissue uptake, and improving biodistribution of therapeutic compounds to target sites. Herein we present recent advances in liposome drug delivery by analyzing the main structural features of liposome nanocarriers which strongly influence their interaction in solution. More specifically, we will focus on the analysis of the relevant soft interactions involved in drug delivery processes which are responsible of main behaviour of soft nanocarriers in complex physiological fluids. Investigation of the interaction between liposomes at the molecular level can be considered an important platform for the modeling of the molecular recognition processes occurring between cells. Some relevant strategies to overcome the biological barriers during the drug delivery of the nanocarriers are presented which outline the main structure-properties relationships as well as their advantages (and drawbacks) in therapeutic and biomedical applications.

Citing Articles

Targeted Sodium Acetate Liposomes for Hepatocytes and Kupffer Cells: An Oral Dual-Targeted Therapeutic Approach for Non-Alcoholic Fatty Liver Disease Alleviation.

Hou Y, Gao X, Gong J, Dong X, Hao Y, Zhai Z Nutrients. 2025; 17(5).

PMID: 40077800 PMC: 11901740. DOI: 10.3390/nu17050930.

Nanotechnology and Artificial Intelligence in Dyslipidemia Management-Cardiovascular Disease: Advances, Challenges, and Future Perspectives.

Mlynarska E, Bojdo K, Frankenstein H, Kustosik N, Mstowska W, Przybylak A J Clin Med. 2025; 14(3).

PMID: 39941558 PMC: 11818864. DOI: 10.3390/jcm14030887.

Liposomal Formulations: A Recent Update.

Agrawal S, Baliga V, Londhe V Pharmaceutics. 2025; 17(1).

PMID: 39861685 PMC: 11769406. DOI: 10.3390/pharmaceutics17010036.

Tracking Drugs and Lipids: Quantitative Mass Spectrometry Imaging of Liposomal Doxorubicin Delivery and Bilayer Fate in Three-Dimensional Tumor Models.

Lopez A, Holbrook J, Kemper G, Lukowski J, Andrews W, Hummon A Anal Chem. 2024; 96(22):9254-9261.

PMID: 38778440 PMC: 11646454. DOI: 10.1021/acs.analchem.4c01586.

Development of finely tuned liposome nanoplatform for macrophage depletion.

Choi T, Yoo R, Park J, Kim J, Ann Y, Park J J Nanobiotechnology. 2024; 22(1):83.

PMID: 38424578 PMC: 10903058. DOI: 10.1186/s12951-024-02325-7.

References

Sercombe L, Veerati T, Moheimani F, Wu S, Sood A, Hua S . Advances and Challenges of Liposome Assisted Drug Delivery. Front Pharmacol. 2015; 6:286. PMC: 4664963. DOI: 10.3389/fphar.2015.00286. View

Paleos C, Tsiourvas D, Sideratou Z . Hydrogen bonding interactions of liposomes simulating cell-cell recognition. A review. Orig Life Evol Biosph. 2004; 34(1-2):195-213. DOI: 10.1023/b:orig.0000009840.53758.c2. View

Gref , Luck , Quellec , MARCHAND , Dellacherie , HARNISCH . 'Stealth' corona-core nanoparticles surface modified by polyethylene glycol (PEG): influences of the corona (PEG chain length and surface density) and of the core composition on phagocytic uptake and plasma protein adsorption. Colloids Surf B Biointerfaces. 2000; 18(3-4):301-313. DOI: 10.1016/s0927-7765(99)00156-3. View

Immordino M, Dosio F, Cattel L . Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. Int J Nanomedicine. 2007; 1(3):297-315. PMC: 2426795. View

Eloy J, de Souza M, Petrilli R, Barcellos J, Lee R, Marchetti J . Liposomes as carriers of hydrophilic small molecule drugs: strategies to enhance encapsulation and delivery. Colloids Surf B Biointerfaces. 2014; 123:345-63. DOI: 10.1016/j.colsurfb.2014.09.029. View

Kneidl B, Peller M, Winter G, Lindner L, Hossann M . Thermosensitive liposomal drug delivery systems: state of the art review. Int J Nanomedicine. 2014; 9:4387-98. PMC: 4172103. DOI: 10.2147/IJN.S49297. View

Needham D . Avidin-biotin interactions at vesicle surfaces: adsorption and binding, cross-bridge formation, and lateral interactions. Biophys J. 1996; 70(3):1391-401. PMC: 1225064. DOI: 10.1016/S0006-3495(96)79697-2. View

Chen J, He C, Lin A, Gu W, Chen Z, Li W . Thermosensitive liposomes with higher phase transition temperature for targeted drug delivery to tumor. Int J Pharm. 2014; 475(1-2):408-15. DOI: 10.1016/j.ijpharm.2014.09.009. View

Geng S, Yang B, Wang G, Qin G, Wada S, Wang J . Two cholesterol derivative-based PEGylated liposomes as drug delivery system, study on pharmacokinetics and drug delivery to retina. Nanotechnology. 2014; 25(27):275103. DOI: 10.1088/0957-4484/25/27/275103. View

10.

Miller C, Bondurant B, McLean S, McGovern K, OBrien D . Liposome-cell interactions in vitro: effect of liposome surface charge on the binding and endocytosis of conventional and sterically stabilized liposomes. Biochemistry. 1998; 37(37):12875-83. DOI: 10.1021/bi980096y. View

11.

Freese C, Gibson M, Klok H, Unger R, Kirkpatrick C . Size- and coating-dependent uptake of polymer-coated gold nanoparticles in primary human dermal microvascular endothelial cells. Biomacromolecules. 2012; 13(5):1533-43. DOI: 10.1021/bm300248u. View

12.

Khaja F, Jayawardena D, Kuzmis A, Onyuksel H . Targeted Sterically Stabilized Phospholipid siRNA Nanomedicine for Hepatic and Renal Fibrosis. Nanomaterials (Basel). 2017; 6(1). PMC: 5302539. DOI: 10.3390/nano6010008. View

13.

Chen S, Yang K, Tuguntaev R, Mozhi A, Zhang J, Wang P . Targeting tumor microenvironment with PEG-based amphiphilic nanoparticles to overcome chemoresistance. Nanomedicine. 2015; 12(2):269-86. PMC: 4789173. DOI: 10.1016/j.nano.2015.10.020. View

14.

Assaraf Y, Leamon C, Reddy J . The folate receptor as a rational therapeutic target for personalized cancer treatment. Drug Resist Updat. 2014; 17(4-6):89-95. DOI: 10.1016/j.drup.2014.10.002. View

15.

Lombardo D . Modeling dendrimers charge interaction in solution: relevance in biosystems. Biochem Res Int. 2014; 2014:837651. PMC: 3955673. DOI: 10.1155/2014/837651. View

16.

Romero E, Morilla M . Highly deformable and highly fluid vesicles as potential drug delivery systems: theoretical and practical considerations. Int J Nanomedicine. 2013; 8:3171-86. PMC: 3754763. DOI: 10.2147/IJN.S33048. View

17.

Campbell R, Ying B, Kuesters G, Hemphill R . Fighting cancer: from the bench to bedside using second generation cationic liposomal therapeutics. J Pharm Sci. 2008; 98(2):411-29. DOI: 10.1002/jps.21458. View

18.

Wu J, Lee A, Lu Y, Lee R . Vascular targeting of doxorubicin using cationic liposomes. Int J Pharm. 2007; 337(1-2):329-35. DOI: 10.1016/j.ijpharm.2007.01.003. View

19.

Lombardo D, Micali N, Villari V, Kiselev M . Large structures in diblock copolymer micellar solution. Phys Rev E Stat Nonlin Soft Matter Phys. 2004; 70(2 Pt 1):021402. DOI: 10.1103/PhysRevE.70.021402. View

20.

Campbell R, Fukumura D, Brown E, Mazzola L, Izumi Y, Jain R . Cationic charge determines the distribution of liposomes between the vascular and extravascular compartments of tumors. Cancer Res. 2002; 62(23):6831-6. View